Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign

Core Insights - Quoin Pharmaceuticals has released the second episode of its "Living with Netherton" video series, featuring a 79-year-old patient, Norma Coles, who has lived with Netherton Syndrome for decades, highlighting the need for awareness and treatment [1][2][4] - The company aims to raise awareness and improve education regarding Netherton Syndrome, which currently has no FDA-approved treatment, emphasizing the urgency for effective therapeutic options [2][5] Company Overview - Quoin Pharmaceuticals is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products for rare and orphan diseases [1][7] - The company is committed to addressing unmet medical needs and has a pipeline that includes four products targeting various rare conditions, including Netherton Syndrome [7] Product Development - Quoin's lead product candidate, QRX003, is currently undergoing evaluation in four clinical trials for the treatment of Netherton Syndrome, with initial data showing improvements in skin healing and quality of life [5][6] - QRX003 is a topical lotion designed to normalize skin-shedding processes and strengthen the skin barrier, addressing the underlying issues of Netherton Syndrome [6] Campaign and Advocacy - The NETHERTON NOW campaign is central to Quoin's efforts to raise awareness and support for individuals affected by Netherton Syndrome, sharing real patient experiences to foster understanding [4][5] - The company emphasizes the importance of patient stories, like that of Norma Coles, to illustrate the challenges faced by those living with this rare genetic disorder [2][5]